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Abstract
Background: Spontaneous regression/complete resistance (SR/CR) mice are a unique colony of mice that possess an 
inheritable, natural cancer resistance mediated primarily by innate cellular immunity. This resistance is effective against 
sarcoma 180 (S180) at exceptionally high doses and these mice remain healthy.
Methods: In this study, we challenged SR/CR mice with additional lethal transplantable mouse cancer cell lines to 
determine their resistance spectrum. The ability of these transplantable cancer cell lines to induce leukocyte infiltration 
was quantified and the percentage of different populations of responding immune cells was determined using flow 
cytometry.
Results: In comparison to wild type (WT) mice, SR/CR mice showed significantly higher resistance to all cancer cell 
lines tested. However, SR/CR mice were more sensitive to MethA sarcoma (MethA), B16 melanoma (B16), LL/2 lung 
carcinoma (LL/2) and J774 lymphoma (J774) than to sarcoma 180 (S180) and EL-4 lymphoma (EL-4). Further 
mechanistic studies revealed that this lower resistance to MethA and LL/2 was due to the inability of these cancer cells 
to attract SR/CR leukocytes, leading to tumor cell escape from resistance mechanism. This escape mechanism was 
overcome by co-injection with S180, which could attract SR/CR leukocytes allowing the mice to resist higher doses of 
MethA and LL/2. S180-induced cell-free ascites fluid (CFAF) co-injection recapitulated the results obtained with live 
S180 cells, suggesting that this chemoattraction by cancer cells is mediated by diffusible molecules. We also tested for 
the first time whether SR/CR mice were able to resist additional cancer cell lines prior to S180 exposure. We found that 
SR/CR mice had an innate resistance against EL-4 and J774.
Conclusions: Our results suggest that the cancer resistance in SR/CR mice is based on at least two separate processes: 
leukocyte migration/infiltration to the site of cancer cells and recognition of common surface properties on cancer 
cells. The infiltration of SR/CR leukocytes was based on both the innate ability of leukocytes to respond to chemotactic 
signals produced by cancer cells and on whether cancer cells produced these chemotactic signals. We found that 
some cancer cells could escape from SR/CR resistance because they did not induce infiltration of SR/CR leukocytes. 
However, if infiltration of leukocytes was induced by co-injection with chemotactic factors, these same cancer cells 
could be effectively recognized and killed by SR/CR leukocytes.
Background
SR/CR mice are a unique colony of cancer-resistant mice
derived from a single male BALB/c mouse that unexpect-
edly survived challenges with the extremely aggressive
mouse cancer cell line S180 at doses up to several million
times greater than the lethal dose for WT mice [1-3]. This
resistance was remarkable since S180-induced malig-
nancy with rapid lethality has not been effectively treated
previously by any other existing therapy. The SR/CR trait
was found to be inheritable in an autosomal dominant
manner and has subsequently been bred into over 2000
descendants in several inbred mouse strains. This domi-
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leukocytes of the innate immune system and does not
require any prior manipulation. However, the trait could
not be mapped to a specific chromosome region after
numerous attempts by either backcross or congenic
breeding strategies (unpublished results), suggesting that
the responsible genetic element may not reside at a fixed
chromosomal location. When SR/CR mice are challenged
repeatedly with S180, the composition of infiltrating leu-
kocytes remains primarily leukocytes of innate immunity
[4]. The leukocytes of SR/CR mice can be transferred to
sensitive wild-type (WT) mice for prevention and treat-
ment of established malignancies in immune-compatible
recipients without adverse side-effects [4].
Another intriguing property of the resistance in SR/CR
mice is that they are healthy throughout their lifespan
suggesting that normal cells in these mice are not harmed
by the anticancer response that targets cancer cells with
exceptionally high specificity [2]. The cancer resistant
phenotype can be retained for life if the mice are fre-
quently challenged with cancer cells. Isolated SR/CR leu-
kocytes display in vitro cytolytic activity against a wide
array of lethal transplantable mouse cancer cell lines that
are distinct in origin, morphology and cellular properties
[2,3]. Meanwhile, transformed but non-cancerous cells,
such as CHO or NIH-3T3, are not killed by the SR/CR
leukocytes in vitro[4].
Upon challenge with S180 tumor cells, the response of
SR/CR mice to cancer cells involves three sequential yet
distinct cellular processes of the leukocytes [5]. First,
there is a rapid infiltration of SR/CR leukocytes to the site
of cancer. This process requires the leukocytes to sense a
chemoattractant gradient before making unidirectional
movement from their storage sites, such as the bone mar-
row, spleen, peripheral lymph nodes and circulation,
toward the higher end of the chemoattractant gradient.
Meanwhile, a clearly-defined chemoattractant gradient
must be established by cancer cells with the higher end of
the gradient at the cancer site. Second, upon arrival at the
cancer site, SR/CR leukocytes make tight physical contact
with the surface of cancer cells, exemplified by rosette
formation between cancer cells and leukocytes. This pro-
cess requires SR/CR leukocytes to recognize unique sur-
face properties of live cancer cells to allow surface
binding between the plasma membranes of leukocytes
and cancer cells. Third, upon surface contact, leukocytes
deliver effector mechanisms to cause damage to the
plasma membranes, swelling and eventual rupture of
cancer cells. This final process involves, but is not limited
to, several known common effector mechanisms, such as
degranulation of neutrophilic granulocytes. The third
process is not unique to SR/CR mice since these effector
mechanisms have been reported previously in WT mice
in the killing of cancer cells [6-8]. However, the first two
processes were unique to SR/CR mice since WT leuko-
cytes are unable to respond to the same cancer cells with
either infiltration or rosette formation.
Based on the in vitro observations and other in vivo
observations, this unique phenotype appears to be a true
general resistance against cancer cells that may extend to
additional mouse cancer cell lines. It would be helpful in
elucidating the mechanism of SR/CR resistance if we
were to identify cancer cell lines that could escape this
resistance. Here, we report our findings.
Methods
Cell Lines and Mouse Strains
S180, EL-4, LL/2, B16, and J774 cell lines were purchased
from American Type Culture Collection and propagated
in culture according to the manufacturer's protocol.
MethA were a kind gift from Dr. Lloyd Old (Ludwig Insti-
tute for Cancer Research, New York). BALB/c mice were
purchased from Charles River Laboratory and C57BL/6
mice were purchased from the Jackson Laboratory. SR/
CR mice (1, 4) were bred at the Animal Research Pro-
grams of Wake Forest University (WFU) Health Sciences.
Mice were housed in plastic cages covered with individ-
ual air filter tops, containing corncob shavings as bed-
ding, allowed free access to water and regular chow and
exposed to a 12-hr fluorescent light/dark cycle. All ani-
mal procedures were conducted according to Institu-
tional Animal Care and Use Committee guidelines and
the National Institutes of Health Guide for the Care and
Use of Animals and with all protocols and procedures
approved by the IACUC of the WFU Health Sciences.
Mature mice (~2-6 months old) were used for all experi-
ments unless specifically noted elsewhere.
SR/CR In Vivo Resistance
SR/CR and WT mice were injected with the indicated
number of cancer cells i.p. and the ability of mice to resist
the cells was determined by survival. Moribund mice
were euthanized. Cell-free ascites fluid (CFAF) was
obtained by collection of ascites fluid from WT mice that
developed S180 induced ascites. This ascites fluid was
spun twice at 400 g for 5 minutes each, followed by one
spin at 3000 g for 5 minutes with the cell free supernatant
collected after each spin. This CFAF was then used fresh
for subsequent experiments. In the co-injection experi-
ments, 2 ml of CFAF was co-injected with MethA or LL/2
and these mice then received weekly injections of CFAF
for the duration of the experiment.
Immune Infiltration in Response to Cancer Cell Lines and 
CFAF
SR/CR or WT mice were injected i.p. with the indicated
cancer cell line or CFAF. Heat inactivated CFAF was
obtained by heating CFAF for 15 minutes at 100°C in a
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< 5 kD were obtained using Amicon Ultra 5 k centrifugal
devices (Millipore, Billerica, MA) according to the manu-
facturer's instructions. Briefly, total CFAF was placed in
the upper chamber of the centrifugal device and then
spun at 3000 g for 20 minutes separating the > 5 kD frac-
tion into the top chamber and the < 5 kD fraction into the
bottom of the tube. A heat inactivated sample of the < 5
kD fraction was obtained by heating this fraction for 15
minutes at 100°C in a water bath. Six hours after injection
the peritoneal cavity was lavaged and the number of cells
was quantitated using a cytometer. For each injection
group, n >= 4.
Flow Cytometry
Cells from peritoneal lavages were stained with specific
antibodies to the cell surface markers Ly6G, NK1.1, F4/
80, CD11c, CD19, CD4, and CD8 (BD Pharmingen, San
Diego, CA) according to standard procedures recom-
mended by Pharmingen. Briefly, 400,000 cells from the
peritoneal lavage were added in 100 μl of FMF medium
(PBS w/1% FBS) in 12 × 75 mm flow tubes that were spun
at 400 g × 5 minutes. The supernatant was removed and
the cells were resuspended in 50 μl of 5 μg/ml FITC-con-
jugated antibody (Ly6G, NK1.1, F4/80, CD11c, CD19,
CD4, or CD8) or FMF medium alone as a control and
incubated 30 minutes on ice in the dark. The cells were
then washed twice with 100 μl of FMF medium and then
resuspended in 300 μl of FMF medium keeping the sam-
ples in the dark as much as possible. The samples were
then analyzed on a FACSCalibur flow cytometer (BD Bio-
science, Mountain View, CA). Forward and side scatter
gain settings were tuned to sort live cells from cell frag-
ments. The total value for these seven markers was arbi-
trarily set at 100% for each sample to allow comparison
between groups and for each injection group n >= 4.
S180, MethA, and LL/2 were each tested and found to
have no reactivity to any of the cell surface markers used.
Results
SR/CR Mice Resist a Broad Array of Lethal Mouse Cancer 
Cell Lines
To determine the respective maximum tolerated doses
(MTD), we challenged SR/CR mice and control WT mice
with various lethal mouse cancer cell lines at different
doses and measured the disease-free survival of the mice.
SR/CR mice were first identified by their ability to survive
2 standard screens with 2 × 10e5 and 5 × 10e6 S180 i.p.,
which always induced lethality in WT mice. The mice
were then divided into groups that were challenged with
other cancer cells at different doses. SR/CR mice in the
BALB/c background were challenged with J774 lym-
phoma (MHC haplotype H2d) or MethA sarcoma (H2d)
cells. SR/CR mice in the C57BL/6 congenic background
(generations n8 or later) were challenged with EL-4 lym-
phoma (H2b), LL/2 lung carcinoma (H2b), B16 mela-
noma (H2b) or S180 sarcoma (H2q). All WT mice died
with i.p. doses of 10e3 cells or fewer with all cancer cell
lines tested. The MTD of LL/2 for WT mice was less than
100 cells. As few as one viable EL-4 has been reported
previously to be lethal in WT mice [9]. In the BALB/c
background, all SR/CR mice survived 5 × 10e4 J774
before they began to die at higher doses, while 70% of
mice challenged with 10e5 MethA survived. In the
C57BL/6 background, all SR/CR mice survived with 8 ×
10e7 S180 before they began to die at higher doses. No
death in SR/CR mice was observed with doses up to 2 ×
10e8 for EL-4. The survival of C57BL/6 SR/CR mice chal-
lenged with B16 and LL/2 was greatly reduced with 40%
surviving when challenged with 10e3 cells in both groups
(Figure 1). Although no mice survived challenge with B16
or LL/2 at higher doses, the average survival time of SR/
CR mice at 5 × 10e4 B16 was greatly increased (~34 days)
compared to WT mice (~21 days).
Resistance of naïve SR/CR pups to cancer cells other than 
S180
We injected naïve pups, age 6-8 weeks, with cancer cell
lines other than S180 initially to determine if resistance to
these cell lines was simply a result of cross-vaccination
from antigens shared with S180 or if it was a result of
innate recognition of a common surface property shared
between different cancer cell lines. SR/CR mice had never
previously been tested for their ability to resist additional
cancer cell lines without first being able to survive chal-
lenge with S180. The naïve pups were obtained from our
routine breeding scheme in which one C57BL/6 SR/CR
parent is crossed with a C57BL/6 WT parent. In this
breeding scheme, 30-40% of the naive pups were
expected to survive the initial challenge with S180. Five
weeks after the naïve pups were given 10e6 EL-4 as their
first cancer challenge, 22 of 35 pups (65%) survived and
remained apparently healthy (Figure 2). When naïve pups
were first screened with J774 at 5 × 10e4, 1 of 9 pups sur-
vived.
S180 or CFAF Enhances the Resistance of SR/CR mice to 
MethA and LL/2
It was somewhat surprising that the resistance of SR/CR
mice against some other cancer cell lines was so much
weaker than that against S180 and EL-4, whereas our in
vitro assay results show that the SR/CR leukocytes could
kill all of these cancer cell lines with similar efficiencies
[[2], Z.C. unpublished results]. The increased sensitivity
of SR/CR mice to MethA and LL/2 suggested that a fail-
ure might have occurred at one or more of the three
required stages of leukocyte action for the anticancer
response. We set out to examine which of the three
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this failure of the anticancer response. If the increased
sensitivity was caused by a failure of LL/2 cells in immune
attraction, the resistance should be restored in SR/CR
mice when LL/2 were co-injected with live cancer cells
that were known to induce leukocyte infiltration, such as
S180. To test this hypothesis, we mixed 2 × 10e5 LL/2
cells with 10e6 S180 cells and co-injected them i.p. into
SR/CR mice. All of the co-injected SR/CR mice survived,
whereas all of the co-injected WT mice died. A nearly
identical result was achieved when LL/2 was co-injected
with 10e6 irradiated S180 (25 Gy) that were alive for sev-
eral days but were not proliferating. To further test the
hypothesis that the resistance to LL/2 at 2 × 10e5 was
restored by simply provoking leukocyte migration, we
examined if S180-induced CFAF could achieve the same
effect as the live or irradiated S180. CFAF (cell-free
ascites fluid) is the immediate liquid environment pro-
duced as the S180 cells grow in the peritoneum of WT
mice. If the enhanced survival from the co-injection was
truly mediated by leukocyte migration as a result of dif-
fusible chemoattractants from S180, CFAF should con-
tain all the diffusible chemoattractants and should be able
to recapitulate the enhanced survival observed with live
S180 cells to some extent. Indeed, when 2 × 10e5 LL/2
were co-injected with CFAF (with 2 ml weekly), a clear
Figure 1 SR/CR mice resist a broad range of lethal cancer cell lines at different doses. The percentage of SR/CR mice that were able to survive 
challenge with J774, MethA, EL-4, S180, B16, or LL/2 was determined empirically. Mice were monitored for at least 60 days after challenge. SR/CR 
C57BL/6 mice were challenged with 10e3 or 5 × 10e4 B16 or LL/2. SR/CR C57BL/6 mice were also challenged with 0.8 × 10e7, 1.6 × 10e8, 2.2 × 10e8, 
or 3.2 × 10e8 S180 or 2.5 × 10e7, 5 × 10e7, 10e8, or 2 × 10e8 EL-4. SR/CR BALB/c mice were challenged with 10e5, 2 × 10e5, 4 × 10e5, or 10e6 MethA 
or 5 × 10e4, 10e6, or 10e7 J774. WT mice uniformly died at all doses with all cell lines tested. At least 5 mice were tested for any given dose of tumor 
cells injected.
Figure 2 Naïve SR/CR pups resist the initial challenge with EL-4 
and J774. Pups from an SR/CR × WT cross were challenged with 10e6 
EL-4 prior to being challenged with any other cancer cell line and 22 
out of 35 pups survived. Pups from an SR/CR × WT cross that were chal-
lenged with 5 × 10e5 and a second challenge with 5 × 10e6 S180 have 
a historical survival rate of ~30% [1,2]. When nine pups from an SR/CR 
× WT cross were challenged with 5 × 10e4 J774 prior to being chal-
lenged with any other cell line, one mouse survived. All WT mice chal-
lenged with EL-4, S180, and J774 at the indicated doses uniformly died. 
Mice were monitored for at least 60 days after challenge.
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Figure 3 S180 or cell free ascites fluid (CFAF) enhances SR/CR resistance. SR/CR or WT mice were challenged with 2 × 10e5 LL/2 (upper panel) 
or 10e6 MethA (lower panel) i.p. either alone or with 10e6 S180, 10e6 irradiated S180, or weekly injections of CFAF and survival curves were generated. 
The number of mice in each group is indicated in the figure.
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similar result was obtained for the resistance to MethA
co-injected with S180, irradiated S180 and CFAF (Figure
3 lower panel) and preliminary results indicate that S180
also enhances the survival of SR/CR mice challenged with
higher doses of B16 (data not shown).
S180 only enhances the resistance of SR/CR mice to LL/2 
locally
The improved survival in SR/CR mice co-injected with
S180 or CFAF could be the consequence of two distinct
events; higher infiltration of SR/CR leukocytes or
improved effector function by systemic activation of SR/
CR leukocytes induced by S180 coinjection. To determine
which of the processes predominated, we examined the
ability of S180 to enhance SR/CR resistance to LL/2 when
injected in the same site or at a remote site (Figure 4).
Our results indicate that S180 only enhances resistance to
LL/2 when injected at the same site.
S180 and CFAF induce leukocyte infiltration in SR/CR mice
The need for co-injection suggested that the ability to
induce leukocyte infiltration along with the number of
infiltrating leukocytes may be directly related to the num-
ber of cancer cells the SR/CR mice can resist, with a
strong infiltration resulting in a higher MTD. We hypoth-
esized that the low-MTD cancer cells (LL/2 and MethA)
should have lower activity for inducing SR/CR leukocyte
infiltration, whereas the high-MTD cancer cells (S180)
should have higher activity for inducing leukocyte infil-
tration. To test this hypothesis, we quantified the number
of infiltrating cells in the peritoneum and used flow
cytometry to profile the cell types of the infiltrating leu-
kocytes based on surface markers six hours after being
challenged with different cancer cells. Aliquots of leuko-
cytes were specifically labeled with surface antibodies for
neutrophils (Ly6G positive), macrophages (F4/80 posi-
tive), natural killer cells (NK1.1 positive), dendritic cells
(CD11c positive), B cells (CD19 positive), helper T cells
(CD4 positive), and cytolytic T cells (CD8 positive) cells
and then subjected to analysis by flow cytometry. The
sum of these seven markers was arbitrarily set at 100% to
allow comparison between different groups. The most
noticeable differences were in the numbers of neutrophils
and macrophages in response to S180 or CFAF between
WT and SR/CR mice, while levels of B cells remained
fairly consistent (Figure 5A). It was clear that S180
induced significantly more leukocyte infiltration in SR/
CR mice than MethA and LL/2, and the percentage of
leukocytes was shifted towards innate immune cells, spe-
cifically neutrophils and macrophages. It was interesting
to note that this effect was specific for SR/CR mice since
cancer cells or CFAF appeared to have an inhibitory
effect on WT leukocyte infiltration (Figure 5C). CFAF
provoked the largest leukocyte infiltration, consistent
with the idea that the highest concentration of diffusible
chemoattractants would accumulate in the peritoneal
fluid over several days in the presence of a large number
of live S180 cells. We also characterized some of the bio-
chemical properties of the chemoattractants in S180-
induced CFAF. When CFAF was fractioned through an
Amicon Ultra 5 k centrifugal device, most of the
chemoattraction activity was recovered in the filtered-
through fraction, suggesting that the chemoattractants
were smaller than 5 kilo-Dalton. Furthermore, boiling
CFAF for 10 min abolished most of the chemoattracting
activity, suggesting that the chemoattractants were heat
sensitive (Figure 5D).
Discussion
In the present study, we characterized the ability of SR/
CR mice to resist additional lethal cancer cell lines in vivo,
and showed that SR/CR mice are able to resist these cell
lines at higher doses than WT mice. However, SR/CR
mice were able to resist some cancer cell lines at excep-
tionally high doses (high-MTD), whereas other cancer
cell lines were only resisted at moderate or lower doses
(low-MTD). We found that co-injection with either S180
or CFAF, both capable of inducing massive leukocyte
infiltration specifically in SR/CR mice, was able to
increase the level of resistance of SR/CR mice to cell lines
with otherwise low-MTD.
Cancer cells may undergo selection to avoid detection
by the immune system, a process termed cancer
Figure 4 S180 only enhances SR/CR resistance locally. SR/CR mice 
were challenged with 2 × 10e5 LL/2 i.p. either alone or with 10e6 S180, 
either i.p. or s.c., and the survival of mice was monitored. The number 
of mice in each group is indicated in the figure.
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Figure 5 Leukocyte subset composition during challenge with different cancer cell lines. A) SR/CR and WT mice were challenged with 10e5 
cells of the indicated cancer cell line, CFAF, or PBS and responding leukocytes were washed out at six hours, quantitated, stained with Ly6 g (PMN), 
F4/80 (Mac), and CD19 (B-cell) and profiled by flow cytometry. B) Composition of infiltrating immune cells. SR/CR mice were injected with 10e5 cells 
of the indicated cancer cell line or PBS and six hours later the peritoneal cavity was washed out. The peritoneal infiltrate was stained with Ly6 g (PMN), 
F4/80 (Mac), NK1.1 (NK cell), CD11c (dendritic cell), CD19 (B-cell), CD4, and CD8 and profiled by flow cytometry. The total value for these seven markers 
was arbitrarily set at 100% for each sample to allow comparison between groups. Values represent the mean +/- SEM. For each injection group, n >= 
4. C) Immune infiltration in response to cancer cell lines and CFAF. SR/CR or WT mice were injected i.p. with 10e5 cells of the indicated cancer cell line 
or CFAF and six hours later the peritoneal cavity was washed out and the number of cells was quantitated using a cytometer. Values represent the 
mean +/- SEM. For each injection group, n >= 4. D) SR/CR immune infiltration in response to CFAF, heat inactivated CFAF, and small (<5 kD) or large 
(>5 kD) molecules found in CFAF fluid. SR/CR mice were injected as indicated and six hours later the peritoneal cavity was washed out and the number 
of cells was quantitated using a cytometer. Values represent the mean +/- SEM. For each injection group, n >= 4.
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nancy [10]. A variety of tumor-derived factors may con-
tribute to immunosuppressive processes that may extend
immune evasion from the primary site to peripheral sites
in patients with cancer [11]. The results from our experi-
ments suggest that cancers with low-MTD escape from
SR/CR anticancer immunity because they do not produce
sufficient chemoattractants. These low-MTD cancer cell
lines are capable of being eradicated in SR/CR mice at
lower doses, presumably by the less than 2 × 10e6 resi-
dent leukocytes usually present locally in the peritoneal
cavity. At higher doses, however, the growth of these low-
MTD cancer cell lines may outpace the killing ability of
these limited resident leukocytes. This is in contrast to
cell lines such as S180 that are able to induce a very large
infiltration of leukocytes. The larger numbers of infiltrat-
ing SR/CR leukocytes are apparently capable of killing a
much larger number of cancer cells.
Although the outcome of the co-injection experiment
with S180 and CFAF was somewhat unexpected, the
results, coupled with our previous work demonstrating
that S180, MethA, and LL/2 were killed in an in vitro
assay [2], suggest that the ability to induce leukocyte infil-
tration may be the most significant factor between these
cancer cells in their ability to be resisted by SR/CR mice.
There appear to be common surface properties that allow
a variety of cancer cells to be recognized, bound, and
destroyed by SR/CR leukocytes when they are in close
proximity (Figure 6). Our results demonstrate that S180
only enhances resistance against LL/2 locally in SR/CR
mice and argues that the ability of S180 to induce leuko-
cyte infiltration is the critical event in augmenting resis-
tance. While immune infiltration is clearly important for
the eradication of cell lines such as LL/2 and MethA, we
cannot completely exclude the possibility that co-injec-
tion with S180 or CFAF also activates the effector mecha-
nism of SR/CR leukocytes, in addition to the induction of
their infiltration.
The results also suggest that there is a diffusible
chemoattractant gradient established by some cancer
cells. CFAF from S180 contains high levels of these
chemoattractants that are specific for SR/CR leukocytes.
Our results indicate that the most active chemoattrac-
tants are molecules smaller than 5 kD that are heat sensi-
tive. It is currently unclear if these diffusible
chemoattractants were produced by active cellular secre-
tion [11,12], by passive "surface shedding", a physical pro-
cess, from cancer cells [13-16] or indirectly by the
interaction between cancer cells and stromal tissues.
Nevertheless, CFAF offers a good platform for further
biochemical purification and identification of these
chemoattractants. Apparently, chemoattraction of SR/CR
leukocytes is a separate process from recognition of the
common cancer cell surface properties that allow for
local binding and eradication of SR/CR leukocytes, since
some cancer cells can lose the former process while
retaining the properties of the latter. This ability to
induce leukocyte infiltration through chemoattraction
appears to be the reason that SR/CR leukocytes are effec-
tive as a systemic therapy against established S180 can-
cers, but are only locally effective against cancers like LL/
2.
The cancer/immune cell interaction involves events on
either side that influence the ability of the immune sys-
tem to eradicate the cancer. On the cancer side, malig-
nant lesions may range from being highly immune-
attractive (S180) to inducing little immune infiltration
(LL/2). Cancer cells may develop mechanisms that pre-
vent migration of leukocytes to the site of the cancer,
either by turning off the production of inflammatory
molecules that can act as chemoattractants or by produc-
ing molecules that actively inhibit immune cells, such as
TGF-β [17]. Our results indicate that cancer cells and
CFAF may also produce molecules that are directly inhib-
itory to WT leukocytes (Figure 4C). On the host side, leu-
kocytes themselves can vary significantly in any of the
three required stages of leukocyte response. If leukocytes
Figure 6 SR/CR leukocyte migration and cancer destruction. A 
proposed model for SR/CR mediated cancer cell killing. S180 secretes 
chemotactic factors that attract SR/CR leukocytes (SR) to the site of the 
cancer, allowing tight contact between the leukocytes and cancer cells 
to be made which facilitates tumor destruction. LL/2 and MethA pro-
duce little or no chemoattractant and are, therefore, not efficiently 
killed by SR/CR leukocytes. Co-injection of MethA or LL/2 with S180 re-
sults in attraction of SR/CR leukocytes to the site of the cancer and ef-
ficient cell killing of these cancer cell lines. This suggests that some 
cancer cells may escape from SR/CR resistance because they do not in-
duce SR/CR leukocyte infiltration and demonstrates the importance of 
leukocyte infiltration in the SR/CR resistance mechanism.
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of the cancer, or deployment of their effector mechanisms
an effective anticancer response to protect the host can-
not take place. For example, leukocytes may infiltrate the
cancer site but may be unable to recognize and kill the
cancer cells. This has been reported in some melanoma
patients, in whom despite having melanoma-specific T
cells infiltrating the tumor lesions, tumor rejection rarely
occurs [18]. Additionally, the responsiveness of host leu-
kocytes may be influenced by genetics, aging and envi-
ronmental factors.
Our SR/CR model system is very interesting in light of
many recent reports that there is a positive correlation
between tumor infiltrating lymphocytes and the survival
of patients with melanoma, ovarian cancer, bladder can-
cer, glioma, and colon cancer [19-23]. It is worth noting
that in these examples of human cancers the correlation
is with cells of the adaptive immune system, specifically T
lymphocytes, while in the SR/CR mouse the resistance
mechanism is mediated by the innate immune system. A
recent study performed by Galon et al. is particularly
intriguing as it specifically links activation of the cellular
immune response, including macrophages of the innate
immune system, to patient outcomes in colorectal cancer
[24]. They find a significant correlation between expres-
sion of genes of the Th1 response and a beneficial out-
come in risk of relapse after complete removal of the
tumor.
The best case scenario for an anticancer protection
mechanism in a host would be having cancer cells that
secrete a chemoattractant and having leukocytes that can
infiltrate, recognize the cancer cells as foreign, and com-
pletely destroy the cancer. However, the absence of one or
more of these factors could lead to an unfavorable host/
cancer interaction enabling the cancer to escape immu-
nosurveillance resulting in progression of the disease.
When there is no recognition of cancer cells by leuko-
cytes, manipulation of other processes, such as infiltra-
tion, will not improve host survival. However, if
infiltration is the only deficiency, as we observe in SR/CR
mice challenged with LL/2, local delivery of host leuko-
cytes or establishment of a chemoattractant gradient at
the cancer site could achieve therapeutic benefit.
Conclusions
Our results show that SR/CR mice had significantly
higher resistance to all cancer cell lines tested in compar-
ison to wild type (WT) mice. However, there was great
variation in the number of cells that could be resisted by
SR/CR mice across the different cancer cell lines tested. It
appears that this variation is based on the ability of the
cancer cell lines to induce leukocyte infiltration, as co-
injection with chemoattractant factors increased the
number of cancer cells that the SR/CR mice could resist.
We also demonstrate for the first time that SR/CR mice
are able to resist cell lines other than S180 on the initial
challenge. Therefore, it appears that the resistance
against other cancer cells is also innate in nature since it
does not require specific priming with non-self antigens
found on S180. This supports the idea that SR/CR mice
innately recognize a factor that is common on multiple
cancer cell lines but absent on non-neoplastic cells.
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